Clinical Trial Update: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis [Phase 2]

View source ↗

Summary

Phase 2 study of CNTO 1959 (guselkumab) in palmoplantar pustulosis completed to assess efficacy, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis

Drugs mentioned

• CNTO 1959 (guselkumab) (guselkumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Palmoplantaris Pustulosis | Phase 2 | Status: COMPLETED